FDA names drugmakers potentially acting to delay cheap generics

The U.S. Food and Drug Administration on Thursday listed a number of drugmakers it said could be improperly blocking access to their medicines in order to delay generic competition. The FDA said the list contained all of the inquiries about drugs it had received from generic drugmakers since 2005. Releasing the list of drugmakers, which includes Celgene Corp , Johnson & Johnson , Gilead Sciences and Novartis AG , is part of the Trump administration’s efforts to pressure companies to lower drug prices.